This website uses cookies. For more information please contact us or consult our privacy policy.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Daniel Pavin
Daniel Pavin
Partner
London +44 20 7067 2029 dpavin@cov.com Download V-card

Daniel Pavin is a partner in the Corporate Practice and is resident in Covington's London office.

Mr. Pavin has broad non-contentious and contentious experience, with an emphasis on advising companies for whom intellectual property rights are of paramount importance.  In particular, Mr. Pavin advises life sciences clients on their licensing, partnering, collaboration and other strategic and commercial agreements, and on the IP aspects of mergers, acquisitions and strategic investments in the life sciences and technology sectors.  His contentious experience includes advising on contract disputes. 

  • Advising Abingworth on the establishment of and investment in GammaDelta Therapeutics Ltd, an immunotherapy company. GammaDelta Therapeutics has been founded on pioneering research by Professor Adrian Hayday and Dr Oliver Nussbaumer at King's College London and the Francis Crick Institute, funded in part by Cancer Research UK, into gamma delta (γδ) T cells.
  • Medical Research Council Technology, a UK-based medical research charity, in the structured sale of a portion of its royalty interests in Keytruda for US$150 million (£115.6 million), the largest royalty monetization by a non-profit institution outside the United States. 
  • AstraZeneca, along with its global biologics research and development arm, MedImmune, on a collaboration with Moderna Therapeutics to discover, co-develop and co-commercialize messenger RNA (mRNA) therapeutic candidates for the treatment of a range of cancers.
  • AstraZeneca on its acquisition of the core respiratory business of Takeda.
  • A leading provider of on-demand video streaming services on its successful claim against the developer of the underlying software platform for delivery up of source code.
  • Illumina on its strategic alliance agreement with Genomics England in respect of sequencing genomes of patients with cancer and rare diseases, as part of a four-year UK government project to decode 100,000 human genomes by 2017.
  • Isarna Therapeutics GmbH, a German biotechnology company, on a license agreement with Santaris Pharma A/S for access to Santaris' Locked Nucleic Acid technology to develop oligonucleotide product candidates.   
  • Innovacell on a collaboration and licensing agreement with Norgine for Europe (excluding Russia and Turkey), SADC and MENA regions in which Innovacell and Norgine will co-develop, and Norgine will commercialise, ICEF15 - an innovative personalised cell therapy to treat faecal incontinence.
  • Sanofi on a research collaboration agreement with Danish biotech Gubra ApS focusing on the discovery of gut peptides in order to identify novel targets suitable for development of peptide-based drugs for treatment of people with diabetes and obesity.
  • Pharming Group NV on its strategic collaboration with Shanghai Institute of Pharmaceutical Industry for the development, manufacture and commercialisation of new products based on the Pharming technology platform, in which SIPI will have commercialisation rights for the Chinese market for all new products developed and Pharming will retain global rights ex-China.
  • UCB in relation to its strategic partnership with Synosia Therapeutics in which Synosia granted UCB a licence for exclusive, worldwide rights to the development compound SYN-115 and rights to a second compound, SYN-118, for non-orphan indications, both compounds being in Phase II clinical development for the treatment of Parkinson’s disease.
  • Minster Pharmaceuticals PLC, an AIM-quoted drug development company specializing in compounds for the treatment of neurological and psychiatric conditions, on intellectual property aspects of its recommended takeover by Proximagen Neuroscience PLC.   
  • Biocompatibles International plc on numerous transactional matters including:   
    • An option agreement with a major multinational Japanese pharmaceutical company in respect of Biocompatibles’ Drug-Eluting Bead Products in Japan;
    • Distribution agreements with (among others) SciClone Pharmaceuticals and RITA Medical Systems, Inc (now AngioDynamics, Inc) in respect of Biocompatibles’ DC and LC Bead Products; and
    • The sale of Biocompatibles’ cardiovascular business to Abbott Laboratories and eyecare business to the Cooper Group.
  • Australian anti-infective drug development company, Biota Holdings Limited, on:   
    • UK intellectual property aspects of its acquisition of the key assets and programs of UK-based antibacterial drug discovery company, Prolysis Limited; and
    • Its collaboration and licence agreement with a major multinational pharmaceutical company headquartered in Europe relating to a series of antivirals aimed at the treatment of respiratory syncytial virus (RSV).
  • A global medical technology company in respect of a dispute regarding endeavors obligations in a patent and know-how licence for stabilization technology.
  • Communications company, Telefónica O2 UK, on document and data retention and data protection matters.   
  • A range of clients, including service providers to the financial services sector, recruitment consultancies, pension trustees and media companies, on responding to data security breaches and potential liabilities arising from those breaches.   
  • The shareholders of Sibelius Software Limited, the world-leading music notation software developer, on its sale to Avid, the world leader in digital media creation tools for film, video, audio, animation, games, and broadcast professionals.
  • Chambers UK, Life Sciences: Transactional (2012-2017)
  • Chambers UK, Life Sciences (2014-2017)
  • LMG Life Sciences Europe, Life Sciences Star - Financial & Transactional (United Kingdom) (2014-2015)
  • Super Lawyers - London, Computer and IT Law (2013)
  • Chambers UK, Best of the UK - Data Protection (2009-2011)
  • PLC Which Lawyer?, Highly Recommended: Life Sciences - Commercial and Partnering, England (2008-2012)
  • IAM Patent 1000 - The World’s Leading Patent Practitioners (2012-2016)
  • The International Who's Who of Life Sciences Lawyers (2011-2012)
  • Legal 500 UK, Commercial Contracts (2014-2016)
  • Legal 500 UK, Pharmaceuticals and Biotechnology (2012, 2016)
  • Legal 500 UK, IT and Telecoms (2011-2012, 2016)
  • IAM Licensing 250 – The World’s Leading Patent and Technology Licensing Lawyers (2010-2011)